Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.98 |
| ▸ | TOP1 known ✓ | P11387 | 3/20 | 0.77 |
| ▸ | TOP2A known ✓ | P11388 | 3/20 | 0.77 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.59 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.56 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.55 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.98 |
| ▸ | MAPT | P10636 | 4/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.98 |
| ▸ | BLM | P54132 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.98 |
| ▸ | RECQL | P46063 | 1/20 | 0.98 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.98 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.98 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38686 | 0.99 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| SCHEMBL29350649 | 0.99 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| SCHEMBL15969230 | 0.94 | ALDH1A1 (0.90) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| SCHEMBL14453641 | 0.91 | ALDH1A1 (0.85) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL6850585 | 0.90 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL38685 | 0.90 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL29728780 | 0.90 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL659782 | 0.90 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL15545820 | 0.89 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL4950608 | 0.89 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2MAPTMEN1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637669-B2 | Two-dimensional and three-dimensional microarray cell cultures using elastomeric assembly substrates | NUTECH VENTURES (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260139262-A1 | PROTEIN NANOPARTICLE AND METHODS OF USING SAME | THE STATE OF ISRAEL MINI OF AGRICULTURE & RURAL DEVELOPMENT AGRICULTURAL R (IL) | 2026-05-21 | — | — | US | disclosed |
| WO-2026090619-A1 | 3D MULTI-MODAL SHELL FOR ELECTRICAL AND CHEMICAL MONITORING AND SIMULATION | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12611414-B2 | Cysteinyl-proresolving mediators that promote resolution of infection and organ protection | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260083780-A1 | COMPLEX FOR PROMOTING CARTILAGE DIFFERENTIATION COMPRISING CARTILAGE CELL-FREE CRUSH AND STEM CELL AND USE THEREOF | KANGSTEM BIOTECH CO LTD (KR) | 2026-03-26 | — | — | US | disclosed |
| US-20260062668-A1 | CLICK CHEMISTRY LIGAND | UNIV NORTHEASTERN (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260014283-A1 | ULTRASOUND-SENSITIVE PEPTIDE PARTICLES FOR SPATIALLY RESOLVED MOLECULE DELIVERY AND METHODS OF USING THE SAME | PENN STATE RES FOUND (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250354140-A1 | CALCIUM SALTED SPHERICAL NUCLEIC ACIDS | UNIV NORTHWESTERN (US) | 2025-11-20 | — | — | US | disclosed |
| US-12441788-B2 | Anti-müllerian inhibiting substance antibodies and uses thereof | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2025-10-14 | — | — | US | disclosed |
| US-20250302792-A1 | ACTIVE SUBSTANCES FOR MEDICAL USE | INFLAMED PHARMA GMBH (DE) | 2025-10-02 | — | — | US | disclosed |
| US-20220241203-A1 | METHOD FOR PRODUCTION OF LIPOSOMES | UNIVERSIDADE DO MINHO (PT) | 2022-08-04 | — | — | US | disclosed |
| EP-4034560-A1 | ANTI-MÜLLERIAN INHIBITING SUBSTANCE ANTIBODIES AND USES THEREOF | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-08-03 | — | — | EP | disclosed |
| EP-4034151-A1 | USE OF MÜLLERIAN INHIBITING SUBSTANCE INHIBITORS FOR TREATING CANCER | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-08-03 | — | — | EP | disclosed |
| CN-114544567-A | Fluorescent probe combination for detecting cell apoptosis and method for realizing cell apoptosis detection by using double fluorescent markers | 贵州医科大学附属医院 | 2022-05-27 | — | — | CN | disclosed |
| CN-114450304-A | Anti-mullerian tube inhibitor antibody and use thereof | 国家医疗保健研究所 | 2022-05-06 | — | — | CN | disclosed |
| CN-114404615-A | Polypeptide nano micelle preparation, preparation method and application thereof | 国家纳米科学中心 | 2022-04-29 | — | — | CN | disclosed |
| EP-2522983-B2 | Nozzle for particle alignment in fluid flows | MASTERRIND GMBH (DE) | 2022-03-30 | — | — | EP | disclosed |
| US-20220090050-A1 | TRANSFERRIN RECEPTOR-BINDING MOLECULES, CONJUGATES THEREOF AND THEIR USES | UNIVERSITE D'AIX-MARSEILLE (FR) | 2022-03-24 | — | — | US | disclosed |
| WO-2022061176-A1 | METHODS AND SYSTEMS FOR PREDICTING NEURODEGENERATIVE DISEASE STATE | NEW YORK STEM CELL FOUNDATION, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
| US-11241442-B2 | Methods of use for TRP channel antagonist-based combination cancer therapies | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302792-A1 | ACTIVE SUBSTANCES FOR MEDICAL USE | AADAT, CYP1A2, MAOA | GLA 273/4885TOP1 1454/4885TOP2A 1416/4885 |
| US-20260139262-A1 | PROTEIN NANOPARTICLE AND METHODS OF USING SAME | CPN1, CTSA, CSNK2A1 | GLA 766/4885TOP1 2012/4885TOP2A 2162/4885 |
| US-20260062668-A1 | CLICK CHEMISTRY LIGAND | MCU, SPPL2A, CLPX | GLA 4503/4885TOP1 328/4885TOP2A 830/4885 |
| US-20260083780-A1 | COMPLEX FOR PROMOTING CARTILAGE DIFFERENTIATION COMPRISING CARTILAGE CELL-FREE CRUSH AND STEM CELL AND USE THEREOF | COL2A1, MYADM, COL1A1 | GLA 1022/4885TOP1 2834/4885TOP2A 2576/4885 |
| US-12637669-B2 | Two-dimensional and three-dimensional microarray cell cultures using elastomeric assembly substrates | EPCAM, STUB1, MEF2D | GLA 2677/4885TOP1 392/4885TOP2A 120/4885 |
| US-20260014283-A1 | ULTRASOUND-SENSITIVE PEPTIDE PARTICLES FOR SPATIALLY RESOLVED MOLECULE DELIVERY AND METHODS OF USING THE SAME | HDGFL3, HDGF, HM13 | GLA 4575/4885TOP1 2397/4885TOP2A 3057/4885 |
| US-12611414-B2 | Cysteinyl-proresolving mediators that promote resolution of infection and organ protection | CYSLTR2, FPR2, FPR3 | GLA 4527/4885TOP1 3915/4885TOP2A 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.